Lucid Diagnostics Inc.
LUCD
$1.14
-$0.01-0.87%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.28% | 5.01% | 14.74% | 39.89% | 79.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.28% | 5.01% | 14.74% | 39.89% | 79.00% |
| Cost of Revenue | -6.03% | 8.48% | 9.13% | 11.07% | 18.73% |
| Gross Profit | 28.62% | -15.02% | -0.82% | 14.88% | 22.47% |
| SG&A Expenses | 13.54% | 12.42% | 15.14% | 17.74% | 3.05% |
| Depreciation & Amortization | -36.09% | -69.62% | -78.34% | -83.17% | -76.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.83% | 6.25% | 8.13% | 8.30% | -1.01% |
| Operating Income | -7.79% | -6.37% | -7.57% | -6.21% | 5.01% |
| Income Before Tax | -27.41% | -18.89% | -18.44% | -31.46% | 13.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.41% | -18.89% | -18.44% | -31.46% | 13.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.41% | -18.89% | -18.44% | -31.46% | 13.55% |
| EBIT | -7.79% | -6.37% | -7.57% | -6.21% | 5.01% |
| EBITDA | -8.65% | -8.18% | -10.52% | -10.08% | 2.39% |
| EPS Basic | 23.35% | 20.76% | 14.63% | 5.87% | 15.03% |
| Normalized Basic EPS | 44.16% | 35.77% | 25.72% | 18.05% | 22.78% |
| EPS Diluted | 23.35% | 20.76% | 14.63% | 5.87% | 15.03% |
| Normalized Diluted EPS | 44.16% | 35.77% | 25.72% | 18.05% | 22.78% |
| Average Basic Shares Outstanding | 101.68% | 79.82% | 55.87% | 31.99% | 20.95% |
| Average Diluted Shares Outstanding | 101.68% | 79.82% | 55.87% | 31.99% | 20.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |